Open Orphan and Codagenix receive approval from MHRA to conduct Phase I study of intranasal COVID-19 vaccine candidate COVI-VAC

The study will assess the safety and immunogenicity of a single-dose nasal dose in 48 healthy young adult volunteers. COVI-VAC uses entire virus in a weakened form, and claimed to have potential to induce broad antibody, cellular and mucosal immunity with a single dose.

Source:

PharmaTimes